Medicus Pharma shifts SkinJect development focus to Gorlin syndrome, drops sporadic basal cell carcinoma program
MDCX•Commercial modeling for rare-disease strategy
Independent commercial modeling tied to the rare-disease strategy assumed net pricing near $25,800 per treatment, a $1.1 billion U.S. market.
SkinJect development shifts to Gorlin syndrome
Medicus shifted SkinJect development to focus exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions.
Sporadic basal cell carcinoma program to be concluded
Internally sponsored development in sporadic or nodular basal cell carcinoma will be concluded under a capital-efficient portfolio strategy.
Clinical and regulatory plan remains centered on SKNJCT-005
The clinical plan centers on FDA-authorized SKNJCT-005, an NDA-enabling Phase 2b study in Gorlin syndrome.
Regulatory work will continue with the FDA’s orphan office to support orphan-related requests, with additional information to be submitted.
